HTBX - Heat Biologics records biggest one-day gain in over four months

Mohammed Haneefa Nizamudeen/iStock via Getty Images Recording its biggest one-day gain since early February, Heat Biologics (HTBX) has reached a near four-month high today. Last week, the company updated Phase 2 data for its off-the-shelf, allogeneic cell therapy HS-110 in combination with Bristol Myers Squibb's checkpoint inhibitor ((CPI)), OPDIVO (nivolumab) in patients with non-small cell lung cancer ((NSCLC)). In previously treated, CPI naïve patients with advanced NSCLC (Cohort A, n=47), the median overall survival ((mOS)) stood at 24.6 months. mOS was 11.9 months in NSCLC patients who were previously treated with CPI and whose disease had subsequently progressed (Cohort B, n=68), the company said. “This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC,” commented Jeff Wolf, CEO of Heat. “Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial

For further details see:

Heat Biologics records biggest one-day gain in over four months